News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neurotez, Inc. Reports Development of a Method to Isotype the Human TOMM40 Variable-Length Polymorphism



3/22/2011 10:45:44 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--The new Neurotez method will allow for an elegant and rapid way to screen a large number of patient-derived samples and measure the degree of confidence in predicting a subject's risk for getting Alzheimer's disease, based on her/his TOMM40/APOE haplotype. TOMM40 has been implicated as a potential biomarker for those at risk for developing Alzheimer's disease, based on work by Allen Roses' team at Duke University's Deane Drug Discovery Institute.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES